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Abstract
Background: Recent genetic studies have identified a growing number of loci with suggestive evidence of association with
susceptibility to Alzheimer’s disease (AD). However, little is known of the role of these candidate genes in influencing
intermediate phenotypes associated with a diagnosis of AD, including cognitive decline or AD neuropathologic burden.
Methods/Principal Findings: Thirty-two single nucleotide polymorphisms (SNPs) previously implicated in AD susceptibility
were genotyped in 414 subjects with both annual clinical evaluation and completed brain autopsies from the Religious
Orders Study and the Rush Memory and Aging Project. Regression analyses evaluated the relation of SNP genotypes to
continuous measures of AD neuropathology and cognitive function proximate to death. A SNP in the zinc finger protein 224
gene (ZNF224, rs3746319) was associated with both global AD neuropathology (p=0.009) and global cognition (p=0.002);
whereas, a SNP at the phosphoenolpyruvate carboxykinase locus (PCK1, rs8192708) was selectively associated with global
cognition (p=3.57610
24). The association of ZNF224 with cognitive impairment was mediated by neurofibrillary tangles,
whereas PCK1 largely influenced cognition independent of AD pathology, as well as Lewy bodies and infarcts.
Conclusions/Significance: The findings support the association of several loci with AD, and suggest how intermediate
phenotypes can enhance analysis of susceptibility loci in this complex genetic disorder.
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Introduction
Alzheimer’s disease (AD), the most common cause of dementia,
leads to progressive loss of memory and other cognitive domains,
and is characterized pathologically by the accumulation of
extracelluar amyloid plaques and intracellular neurofibrillary
tangles. AD likely develops from an interaction of numerous
genes along with environmental risk factors, each with modest and
incompletely penetrant effects. Linkage studies have identified rare
gene mutations as causal in familial, early age-of-onset AD, but
these Mendelian variants only explain a small fraction of disease
burden in the general population [1]. The identification of
susceptibility loci for sporadic, late age-of-onset AD has been more
challenging, with numerous reports of candidate gene associations,
most of which have not been consistently replicated in follow-up
studies [2–4]. One notable exception is the apolipoprotein E locus
(APOE): the e4 allele is common, increases AD susceptibility 3-fold,
and is estimated to explain at least 10% of the population-
attributable risk of disease [1]. In addition, the APOE e2 allele is a
validated AD protective allele though it is less common, and its
effect size is more modest than e4.
Genome-wide association (GWA) studies have emerged as a
promising approach to identify susceptibility loci in common
diseases with complex genetic inheritance, but until recently, most
GWA scans in AD have been relatively underpowered, and
identified loci have not been consistently replicated [5–14].
Increasing sample size is one approach for boosting statistical
power, and this strategy has recently led to the identification of
several promising new AD susceptibility loci, including CR1, CLU,
and PICALM [15,16]. However, clinical heterogeneity remains a
significant confounder of the case/control study design in AD, due
to the likely inclusion of dementia cases with multiple pathologies,
such as cerebrovascular disease or other neurodegenerative
conditions. In addition, since AD develops following a protracted
pre-clinical phase consisting of mild symptoms, control groups are
susceptible to contamination by latent disease cases. Substantial
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with minimal or no cognitive impairment at death [17]. Subjects
with significant pathology but subclinical disease are likely to dilute
power in an AD case/control association analysis.
One approach to overcoming these obstacles is to study
quantitative intermediate phenotypes. The manifestation of the
AD clinical syndrome is the final culmination of a sequence of
events beginning with genetic and environmental risk factors that
trigger intermediate pathological changes, synapse loss and cell
death, and ultimately cognitive decline and dementia. Outcome
measures selected more proximally along this causal chain are
expected be less confounded and more strongly associated with
susceptibilityloci.Inaddition,comparedtothe dichotomousclinical
diagnosis, quantitative intermediate phenotypes can capture more
of the underlying heritable trait variation, further enhancing
statistical power. Based on this promise, a number of studies have
begun to take advantage of intermediate phenotypes for genetic
association analysis in AD, including neuropsychiatric test measures
[18], MRI imaging data [19,20], biomarkers from blood and CSF
[21,22], and direct measurements of AD pathology [23]. The latter
approach requires access to large study populations with detailed
clinical and neuropathologic characterization. The Religious
Orders Study and Rush Memory and Aging Project are
prospectively following more than 2,300 older persons, all of whom
have agreed to annual clinical evaluation and brain donation at
death. More than 800 autopsies have been completed to date, and
quantitative analyses of amyloid and tangle burden has been
performed on nearly 600. In a recent study of APOE in this cohort,
we found that intermediate cognitive and pathological phenotypes
substantially increase power for genetic association analysis [23]. In
addition, using neuropathologic phenotypes, the association
between APOE and cognitive impairment was previously shown to
be mediated by a sequential cascade of amyloid plaque formation
and subsequent development of neurofibrillary tangle pathology
[24,25]. Therefore, beyond enhancing power for association
analysis, intermediate phenotypes hold the additional promise of
testing mechanistic hypotheses of gene action.
In this study, we extend our previous work to evaluate several
candidate AD susceptibility loci for associations with intermediate
phenotypes relevant to AD. Thirty-two candidate SNPs were
selected based on their discovery in AD GWA studies and/or
evidence from the AlzGene online meta-analyses [2,26]. SNPs
were genotyped in more than 400 subjects with detailed cognitive
and pathological data, allowing assessment of genotype relations to
quantitative AD pathology and cognitive function proximate to
death. We subsequently leveraged the detailed phenotypes
available in our cohorts to dissect the functional pathways that
link genetic variants to cognitive impairment.
Methods
Ethics Statement
Written informed consent and an Anatomic Gift Act were
signed by all Religious Orders Study and Rush Memory and
Aging project participants after the procedures were fully
explained, and both studies were approved by the Institutional
Review Board of Rush University Medical Center. The work
described in this report was additionally approved by the
Institutional Review Boards of the Brigham and Women’s
Hospital and Massachusetts Institute of Technology.
Subjects
Clinical and post-mortem data came from participants in the
Religious Orders Study and Rush Memory and Aging Project, two
longitudinal, epidemiologic clinical-pathologic studies of aging and
AD [17]. In both studies, participants without known dementia at
baseline agreed to annual detailed clinical evaluation and brain
donation at the time of death. Participants in the Religious Orders
Study were older Cathololic nuns, priests and brothers from about
40 groups in 12 states across the United States. Subjects in the
Rush Memory and Aging Project were older, community-dwelling
persons from about 40 retirement communities and subsidized
senior housing facilities across northeastern Illinois. Since 1993,
more than 2,300 persons agreed to participate in these studies.
The overall follow-up rate exceeds 90% of survivors and the
overall autopsy rate exceeds 90% of decedents. Of those subjects
with completed neuropathologic analyses, and following genotyp-
ing quality control filters, 414 persons with genotyping data were
available for analysis in February of 2009 when this study was
initiated (250 from the Religious Orders Study and 164 from the
Rush Memory and Aging Project).
Clinical evaluation
The clinical diagnoses of dementia and AD were made each
year following the recommendations of the joint working group of
the National Institute of Neurologic and Communicative Disor-
ders and Stroke and the AD and Related Disorders Association
[27], as previously described in detail [28]. Probable AD refers to
persons with clinical AD and no other clinical condition
contributing to cognitive impairment and possible AD refers to
persons meeting inclusion criteria for AD who are thought to have
another condition (e.g., stroke) contributing to cognitive impair-
ment. MCI referred to those individuals rated as cognitively
impaired by the neuropsychologist but not demented by the
examining physician, as previously described [29]. At the time of
death, clinical data were reviewed by a neurologist without access
to post-mortem data and a summary diagnostic opinion was
rendered regarding the most likely clinical diagnosis at the time of
death. Level of cognition was based on cognitive testing performed
proximate to death. The Religious Orders Study and Rush
Memory and Aging Project have 19 cognitive performance tests in
common, and use identical analytic procedures to develop
summary statistics. Mini-Mental State Examination [30] was used
to describe the cohort and one test was used for diagnostic
classification purposes only. The remaining 17 tests have been
previously described [17]. Tests were converted to z scores, using
the mean and SD from the baseline evaluation of all participants,
and averaged to yield summary measures of global cognition and
five cognitive domains: episodic memory, semantic memory,
working memory, perceptual speed, and visuospatial ability.
Summary measures minimize floor and ceiling effects and other
sources of random variability. For the mediation analyses
incorporating diagnosis of diabetes, annual clinical evaluations
allowed documentation of history of diabetes and use of
medications to treat diabetes. Diabetes was determined to be
present if the participant was ever taking a medication, such as
insulin or an oral hypoglycemic, to treat diabetes, as determined
by direct inspection of medication containers, or ever reported a
history of diagnosis of diabetes, or both, as previously described
[31].
Neuropathological evaluation
Brain autopsies were performed across the US as previously
described [17]. Bielschowsky silver stain was used to visualize
neuritic plaques, diffuse plaques, and neurofibrillary tangles in
tissue sections from the midfrontal, middle temporal, inferior
parietal, and entorhinal cortices, and the hippocampal CA1 sector.
The neuropathologic diagnosis of AD was made by a board-
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previously reported [17,28]. We classified persons as having
pathologic AD based on intermediate or high likelihood of AD by
National Institute on Aging (NIA)-Reagan criteria using CERAD
estimates of neuritic plaque density and Braak staging of
neurofibrillary pathology [32–34], as previously described [17].
The quantitative composite AD pathology score was based on
counts of neuritic plaques, diffuse plaques and neurofibrillary
tangles as previously described [35,36]. Because the means,
standard deviations, and ranges of the data varied widely for the
pathologic indices, we converted the raw counts to a standard
distribution by dividing each person’s count by the standard
deviation for that particular count and formed a summary
measure by averaging the scaled scores. Because the data were
skewed, square root of the scaled score was used in analyses.
Separate summary measures of neurofibrillary tangles and neuritic
and diffuse plaques were also made. Chronic macroscopic cerebral
infarctions and alpha-synuclein immunoreactive Lewy bodies were
determined as previously described and considered present or
absent for analyses [17].
Genotyping
DNA was extracted from lymphocytes or frozen post-mortem
brain tissue. APOE genotyping was performed by Agencourt
Bioscience Corporation (Beverly, MA) utilizing high throughput
sequencing of codon 112 (position 3937) and codon 158 (position
4075) of exon 4 of the APOE gene on chromosome 19. In addition
to the APOE e4 and e2 alleles, 32 SNPs were selected for
genotyping in our cohort, based on prior evidence from the
literature, as of February, 2009. Thus, the more recently
discovered CR1, CLU, and PICALM [15,16] loci were not included
in this study, but are the focus of a separate study (Chibnik et al.,
submitted). The selected SNPs were equally divided between the
top results of AD case/control GWA studies [5–7,9,10–14] (16
SNPs) and candidate gene association studies (16 SNPs), which
were chosen based on their top ranking in AlzGene meta-analyses
[2]. The 32 candidate SNPs were genotyped using matrix-assisted
laser desorption-ionization time-of-flight mass spectrometry on a
MassARRAY platform (Sequenom). After excluding subjects for
failed genotyping exceeding the 10% threshold, 414 individuals
remained for subsequent analysis (genotyping rate in these subjects
was .99%). All SNP allele frequencies satisfied Hardy-Weinberg
equilibrium (p.0.001). Allele frequencies were not significantly
different between the Religious Orders Study and Rush Memory
and Aging Project subjects, supporting the validity of pooled
analyses.
Statistical Analysis
Given the complementary study designs and similar procedures
for data collection and generation of the cognitive and
neuropathologic outcome traits, we pooled data from the Religious
Orders Study and Rush Memory and Aging Project for our
analyses, consistent with numerous prior studies [17,23]. Genetic
association was performed using the PLINK analysis software
toolkit [37]. Linear regression was used to evaluate the association
of allele genotypes with level of cognition proximate to death in a
2-degree-of-freedom, genotypic test of association, with covariates
included for age, gender, and years of education. In order to refine
the genetic model, we additionally tested selected SNPs using a 1-
degree-of-freedom test to examine for additive, dominant, or
recessive allelic effects. These studies were performed using
PLINK as well as the R statistical computing program (www.r-
project.org). Linear regression modeling in R was used to calculate
residual quantitative trait variance explained, and to perform
statistical mediation analyses. For the case/control association
analysis based on AD clinical diagnosis, logistic regression was
performed in PLINK under both additive and genotypic models,
and again including covariates for age, gender, and education. All
p-values reported are unadjusted for multiple hypothesis testing. A
Bonferroni-corrected significance threshold of p,0.001 was
calculated for the 34 SNPs tested for associations with our two
primary outcomes, a quantitative measure of global cognitive
performance and global AD pathology. Given the high correlation
between the pathologic and cognitive traits, applying an
adjustment for 68 tests would be overly conservative. Otherwise,
the threshold of p,0.01 was selected to indicate suggestive
statistical evidence of association. All other evaluated phenotypes,
including those for AD clinical diagnosis, pathology sub-types, and
cognitive domains were considered secondary analyses.
Results
Associations with global AD pathology and global
cognition
Subject demographics, clinical and neuropathologic diagnoses,
cognitive status, and APOE genotypes for the cohort analyzed in
this study are presented in Table 1. In clinical evaluations
proximate to death, of the 414 subjects in our study cohort, 131
(31.6%) had normal cognition, 98 (23.7%) had mild cognitive
impairment, and 185 (44.7%) were demented (173 met criteria for
possible or probable AD). As expected, a significant proportion
(41.5%) of individuals without dementia satisfied NIA-Reagan
pathological criteria for intermediate or high likelihood AD.
We initially tested for associations between each of the 34
polymorphisms and our two primary outcomes, intermediate
phenotypes representing a measure of global AD pathologic
burden on autopsy and a measure of global cognitive function
proximate to death (Table 2). Linear regression models were used
to examine the relation of SNP genotypes to the quantitative
neuropathologic and cognitive traits in a 2 degree-of-freedom
statistical test, adjusting for the effects of age at death, gender, and
years of education. As expected, APOE e4 was significantly
associated with both cognition (p=3.4610
210) and AD pathology
(p=1.6610
224) in our cohort, whereas an association with APOE
e2 was only seen for the pathological phenotype (p=9.1610
24). In
addition, we found associations with AD intermediate phenotypes
Table 1. Demographic, clinical and pathological
characteristics of the study cohort.
n 414
Mean age, y (SD) 87.1 (6.9)
Male (%) 161 (38.9)
Education, y (SD) 16.5 (3.6)
Mini-Mental State Examination (SD) 21.4 (9.2)
NINCDS clinical AD (%) 173 (41.8)
Mild cognitive impairment (%) 98 (23.7)
Diabetes (%) 78 (18.8)
APOE e4 allele present (%) 121 (29.2)
APOE e2 allele present (%) 64 (15.5)
NIA-Reagan pathological AD (%) 236 (57.6)
Lewy bodies (%) 77 (18.6)
Infarcts (%) 143 (34.5)
doi:10.1371/journal.pone.0011244.t001
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phosphoenolpyruvate carboxykinase 1 (PCK1) genes, both of
which were selected for genotyping based on their identification
in AD case/control GWA studies [6,10]. The ZNF224 SNP
(rs3746319) was associated with both global cognition (p=0.009)
and global AD pathology (p=0.004). In contrast, the PCK1 SNP
(rs8192708) was significantly associated with global cognition
(p=3.57610
24) but not global AD pathology (p=0.056), suggest-
ing that this locus may influence cognitive impairment through
mechanisms other than AD pathology. Besides APOE e4, none of
the SNP associations surpass the currently accepted threshold for
genome-wide significance (p,5.0610
28); however, the association
between PCK1 and global cognition exceeds a Bonferroni-
corrected significance threshold of p,0.001 for 34 independent
tests. Given the high correlation between the pathologic and
cognitive traits, applying an adjustment for 68 tests would be
overly conservative; however, the PCK1 association still exceeds
that standard (p,7610
24).
Although the risk alleles for the associations of both the ZNF224
and PCK1 loci with the intermediate phenotypes in our cohort also
Table 2. Relation of candidate AD polymorphisms to intermediate cognitive and pathologic phenotypes.
Alleles
Global
Pathology
Global
Cognition
Chr SNP Gene Reference
1 Minor/Major MAF
2 (p
3)( p
3)
1 Rs4845378 nicotinic cholinergic receptor (CHRNB2) AlzGene T/G 0.09 0.794 0.475
Rs505058 lamin A/C (LMNA) Grupe et al. 2007 C/T 0.10 0.366 0.606
Rs2584820 regulator of G protein signaling
protein-like 2 (RGSL2)
Liu et al. 2007 G/A 0.05 0.823 0.298
Rs12044355 disruptend in schizophrenia 1 (DISC1) Beecham et al. 2009 C/A 0.35 0.959 0.296
2 Rs1800587 interleukin-1 Alpha (IL1A) AlzGene A/G 0.31 0.371 0.724
Rs1143634 interleukin-1 Beta (IL1B) AlzGene A/G 0.21 0.392 0.907
3 Rs1049296 transferrin (TF) AlzGene T/C 0.15 0.245 0.945
4 Rs727153 lecithin retinol acyltransferase (LRAT) Abraham et al. 2008 C/T 0.48 0.157 0.911
9 Rs7019241 golgi membrane protein 1 (GOLM1) Li et al. 2008 T/C 0.12 0.512 0.705
Rs10868366 golgi membrane protein 1 (GOLM1) Li et al. 2008 T/G 0.12 0.490 0.730
Rs4878104 death associated protein kinase (DAPK1) Li et al. 2006 T/C 0.37 0.508 0.384
10 Rs2306604 transcription factor A, mitochondrial (TFAM) AlzGene G/A 0.47 0.503 0.742
Rs13500 cholesterol 25-hydroxylase (CH25H) AlzGene T/C 0.10 0.368 0.579
Rs2986017 calcium homeostasis modulator 1 (CALHM1) AlzGene A/G 0.26 0.231 0.505
Rs600879 sortilin-related VPS10-containing receptor
(SORCS1)
AlzGene A/G 0.11 0.290 0.849
Rs1903908 CG2039140 Grupe et al. 2007 A/G 0.15 0.846 0.912
11 Rs6265 brain derived neurotrophic factor (BDNF) AlzGene A/G 0.19 0.032 0.347
Rs1385600 GRB2-associated binding protein 2 (GAB2) Reiman et al. 2007 C/T 0.18 0.825 0.966
Rs2373115 GRB2-associated binding protein 2 (GAB2) Reiman et al. 2007 T/G 0.18 0.544 0.981
Rs2070045 sortilin-related receptor (SORL1) AlzGene G/T 0.22 0.182 0.453
Rs3824968 sortilin-related receptor (SORL1) AlzGene A/T 0.30 0.831 0.683
12 Rs11610206 FAM113B Beecham et al. 2009 C/T 0.08 0.227 0.519
14 Rs11159647 14q31.2 Bertram et al. 2008 A/G 0.49 0.968 0.581
17 Rs1554948 tyrosine kinase non-receptor 1 (TNK1) Grupe et al. 2007 A/T 0.46 0.441 0.337
Rs2471738 microtubule associated protein tau (MAPT) AlzGene T/C 0.21 0.533 0.392
Rs1800764 angiotensin converting enzyme (ACE) AlzGene C/T 0.47 0.451 0.489
19 Rs3746319 zinc finger protein 224 (ZNF224) Beecham et al. 2009 A/G 0.16 0.009 0.004
Rs3826656 CD33 Bertram et al. 2008 G/A 0.20 0.258 0.455
Rs3745833 galinin-related receptor (GALP) Grupe et al. 2007 C/A 0.36 0.024 0.288
20 Rs1799990 prion protein (PRNP) AlzGene G/A 0.33 0.727 0.800
Rs8192708 phosphoenolpyruvate carboxykinase 1 (PCK1) Grupe et al. 2007 G/A 0.12 0.056 3.57610
24
23 Rs5984894 protocadherin 11 X-linked (PCDH11X) Carrasquillo et al. 2009 A/G 0.48 0.188 0.624
19 e4 apolipoprotein E (APOE) - 0.16 1.56610
224 3.40610
210
e2 apolipoprotein E (APOE) - 0.08 9.15610
24 0.238
1 SNPs were selected based on AlzGene meta-analyses (ref. 2) or from results of AD GWA studies (refs. 5–7, 9–14).
2 MAF=minor allele frequency.
3 Unadjusted p-values from genotypic regression models, including covariates for age, gender, and years of education.
doi:10.1371/journal.pone.0011244.t002
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that reported in the original GWA studies [6,10]. In the case of
ZNF224, we find that the minor allele, rs3746319
A, is associated
with both increased AD pathologic burden and decreased
cognitive performance; whereas this variant was protective against
AD in the GWA study (G. Beecham and M. Pericak-Vance,
personal communication). Similarly, for PCK1, the minor allele,
rs8192708
G, significantly protected against cognitive decline in our
cohort but was in fact the AD risk allele in the original GWA study
[2]. Interestingly, two subsequent replication analyses of rs8192708
documented associations of decreased AD risk with the minor
allele, consistent with our findings [4,38]. Therefore, while the
effects of the ZNF224 and PCK1 loci on a diagnosis of AD and on
intermediate phenotypes are consistent within our study (and in
two other PCK1 replication studies); they are not consistent with
the original GWA analyses. In the discussion section, we further
address possible explanations for these discrepancies.
Associations with neuritic and diffuse plaques,
neurofibrillary tangles, and cognitive subdomains
The global AD pathology score averages the post-mortem
density of neuritic and diffuse plaques and neurofibrillary tangles
in multiple brain regions; however, we hypothesized that certain
Table 3. Relation of candidate AD polymorphisms to clinical AD diagnosis.
MAF
2 p-value
4
SNP Gene A
1 AD cases controls OR (95% CI)
3 additive genotypic
rs4845378 CHRNB2 T 0.08 0.10 0.77 (0.46–1.28) 0.305 0.509
rs505058 LMNA C 0.08 0.11 0.81 (0.50–1.33) 0.411 0.571
rs2584820 RGSL2 G 0.04 0.06 0.63 (0.31–1.26) 0.191 0.589
rs12044355 DISC1 C 0.35 0.35 1.07 (0.80–1.44) 0.641 0.716
rs1800587 IL1A A 0.30 0.31 0.98 (0.72–1.34) 0.896 0.901
rs1143634 IL1B A 0.19 0.22 0.87 (0.61–1.26) 0.466 0.729
rs1049296 TF T 0.13 0.17 0.76 (0.51–1.14) 0.183 0.285
rs727153 LRAT C 0.48 0.49 1.03 (0.77–1.37) 0.860 0.803
rs7019241 GOLM1 T 0.12 0.12 0.96 (0.60–1.54) 0.871 0.786
rs10868366 GOLM1 T 0.13 0.13 0.94 (0.59–1.50) 0.804 0.761
rs4878104 DAPK1 T 0.37 0.37 0.98 (0.74–1.31) 0.907 0.984
rs2306604 TFAM G 0.48 0.47 1.01 (0.75–1.36) 0.954 0.354
rs13500 CH25H T 0.10 0.10 0.92 (0.58–1.47) 0.731 0.784
rs2986017 CALHM1 A 0.27 0.26 1.08 (0.78–1.48) 0.645 0.827
rs600879 SORCS1 A 0.11 0.11 0.91 (0.56–1.45) 0.683 0.71
rs1903908 CG2039140 A 0.16 0.14 1.14 (0.76–1.71) 0.525 0.707
rs6265 BDNF A 0.19 0.18 1.03 (0.71–1.50) 0.885 0.83
rs1385600 GAB2 C 0.18 0.18 1.03 (0.70–1.51) 0.897 0.73
rs2373115 GAB2 T 0.18 0.18 0.98 (0.66–1.45) 0.913 0.909
rs2070045 SORL1 G 0.21 0.22 0.96 (0.67–1.39) 0.846 0.522
rs3824968 SORL1 A 0.31 0.30 0.98 (0.71–1.35) 0.881 0.891
rs11610206 FAM113B C 0.08 0.08 1.02 (0.58–1.79) 0.946 0.985
rs11159647 14q31.2 A 0.51 0.47 1.17 (0.87–1.57) 0.304 0.588
rs1554948 TNK1 A 0.46 0.46 0.91 (0.68–1.22) 0.519 0.727
rs2471738 MAPT T 0.22 0.20 1.10 (0.77–1.57) 0.606 0.773
rs1800764 ACE C 0.49 0.47 1.06 (0.80–1.42) 0.673 0.507
rs3746319 ZNF224 A 0.19 0.15 1.51 (1.02–2.25) 0.042 0.008
rs3826656 CD33 G 0.20 0.21 0.93 (0.64–1.33) 0.682 0.84
rs3745833 GALP C 0.36 0.36 0.94 (0.69–1.28) 0.699 0.845
rs1799990 PRNP G 0.32 0.33 0.97 (0.71–1.33) 0.844 0.906
rs8192708 PCK1 G 0.09 0.14 0.51 (0.32–0.82) 0.005 0.011
rs5984894 PCDH11X A 0.43 0.52 0.74 (0.58–0.96) 0.021 0.068
e4 APOE - 0.21 0.11 2.67 (1.74–4.11) 7.0610
26 9.63610
26
e2 APOE - 0.08 0.08 0.76 (0.44–1.32) 0.336 0.876
1 A=minor allele.
2 MAF=minor allele frequency.
3 OR=odds ratio, CI=confidence interval.
4 Unadjusted p-values from logistic regression models, under both additive and genotypic models, including covariates for age, gender, and education.
doi:10.1371/journal.pone.0011244.t003
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pathology, in which case the composite pathologic outcome might
dilute statistical power to detect associations. We therefore
performed secondary analyses to determine whether any of the
candidate SNPs tested demonstrate selective or more robust
association signals with separate quantitative measures of plaques
or tangle pathology (Table 4). All analyses were again performed
using linear regression models to test for associations with SNP
genotypes, adjusted for the effects of age, gender, and education. A
SNP at the GALP locus (rs3745833) showed suggestive evidence for
association with diffuse plaques (p=0.003), but not with
neurofibrillary tangles (p=0.373). In contrast, the ZNF224 SNP
(rs3746319) was strongly associated with neurofibrillary tangle
burden (p=1.49610
24), whereas no significant association was
seen with either neuritic plaque (p=0.018) or diffuse plaque
(p=0.290) pathology. Therefore, the association with the tangle
subscore is likely the primary driver for the ZNF224 locus
association with global AD pathology (p=0.009), and the
composite score appears to dilute statistical power. Interestingly,
the PCK1 SNP (rs8192708), which was not associated with the
global pathology measure, did show suggestive evidence for
association with neuritic plaque pathology (p=0.007); however,
this did not appear to explain the strong association with global
cognition (p=3.57610
24), as investigated further below.
Similar to the approach taken with the pathological phenotypes,
we performed secondary analyses to assess whether any of the
Table 4. Relation of polymorphisms to amyloid plaques and neurofibrillary tangles.
Amyloid Pathology Tau Pathology
Diffuse Plaques Neuritic Plaques Neurofibrillary Tangles
SNP Gene (p) (p) (p)
rs4845378 CHRNB2 0.554 0.859 0.137
rs505058 LMNA 0.511 0.307 0.520
rs2584820 RGSL2 0.199 0.235 0.342
rs12044355 DISC1 0.801 0.700 0.715
rs1800587 IL1A 0.265 0.285 0.778
rs1143634 IL1B 0.367 0.222 0.720
rs1049296 TF 0.379 0.274 0.521
rs727153 LRAT 0.041 0.034 0.670
rs7019241 GOLM1 0.766 0.443 0.686
rs10868366 GOLM1 0.673 0.509 0.764
rs4878104 DAPK1 0.673 0.398 0.420
rs2306604 TFAM 0.345 0.231 0.088
rs13500 CH25H 0.288 0.349 0.787
rs2986017 CALHM1 0.748 0.135 0.109
rs600879 SORCS1 0.523 0.198 0.395
rs1903908 CG2039140 0.913 0.866 0.680
rs6265 BDNF 0.117 0.050 0.068
rs1385600 GAB2 0.571 0.580 0.388
rs2373115 GAB2 0.739 0.323 0.168
rs2070045 SORL1 0.052 0.304 0.918
rs3824968 SORL1 0.794 0.806 0.417
rs11610206 FAM113B 0.605 0.071 0.438
rs11159647 14q31.2 0.398 0.616 0.599
rs1554948 TNK1 0.655 0.254 0.474
rs2471738 MAPT 0.401 0.769 0.239
rs1800764 ACE 0.437 0.494 0.627
rs3746319 ZNF224 0.290 0.018 1.49610
24
rs3826656 CD33 0.769 0.558 0.062
rs3745833 GALP 0.003 0.103 0.373
rs1799990 PRNP 0.618 0.674 0.801
rs8192708 PCK1 0.551 0.007 0.080
rs5984894 PCDH11X 0.654 0.166 0.070
e4 APOE 3.74610
216 3.44610
220 6.5610
215
e2 APOE 7.16610
-4 0.001 0.097
doi:10.1371/journal.pone.0011244.t004
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subdomains that comprise the global cognition score. Linear
regression was again used to test for association of each SNP with
separate quantitative trait outcomes representing episodic mem-
ory, semantic memory, working memory, perceptual speed, and
visuospatial ability (Table 5). Episodic memory impairment, the
most characteristic cognitive deficit of AD, was associated with
both the ZNF224 locus (p=0.003) and the PCK1 locus
(p=3.69610
24). ZNF224 was additionally associated with decline
in visuospatial function (p=0.007), and PCK1 showed evidence for
association with semantic memory impairment (p=0.001).
Divergent pathways from genes to cognitive impairment
For the SNPs at the ZNF224 and PCK1 loci, we performed
additional linear regression analyses to refine the genetic model for
the relation with our intermediate phenotypes (additive, dominant,
or recessive), better characterize the strength of the observed
effects, and develop statistical models to test hypotheses about
mechanistic pathways. Our core regression model, consisting of
age at death, gender, and years of education, explained 3% and
7% of the variation in our pathological and cognitive traits,
respectively. Using the optimal dominant model of inheritance, the
ZNF224 SNP (rs3746319) explained an additional 2% (Be-
ta=0.13, p=0.003) of the residual variance in global AD
pathology and 2.1% (Beta=20.39, p=0.002) of the variance in
global cognition (Table 6). We next explored whether the effect of
this locus on AD pathology might mediate its association with
cognition (Table 7). When a term for global AD pathology was
incorporated in our linear regression model, the magnitude of the
association between ZNF224 and global cognition was attenuated
Table 5. Relation of polymorphisms to measures of cognitive performance.
Episodic Memory Semantic Memory Working Memory Perceptual Speed Visuospatial Ability
SNP Gene (p) (p) (p) (p) (p)
rs4845378 CHRNB2 0.315 0.384 0.634 0.959 0.818
rs505058 LMNA 0.413 0.651 0.624 0.972 0.744
rs2584820 RGSL2 0.332 0.317 0.311 0.572 0.630
rs12044355 DISC1 0.548 0.592 0.223 0.700 0.299
rs1800587 IL1A 0.440 0.360 0.761 0.940 0.766
rs1143634 IL1B 0.913 0.588 0.978 0.945 0.520
rs1049296 TF 0.995 0.956 0.702 0.412 0.379
rs727153 LRAT 0.923 0.904 0.423 0.828 0.951
rs7019241 GOLM1 0.516 0.515 0.380 0.245 0.489
rs10868366 GOLM1 0.479 0.641 0.564 0.314 0.490
rs4878104 DAPK1 0.191 0.715 0.934 0.590 0.797
rs2306604 TFAM 0.877 0.554 0.444 0.560 0.126
rs13500 CH25H 0.868 0.407 0.170 0.733 0.143
rs2986017 CALHM1 0.231 0.881 0.594 0.784 0.816
rs600879 SORCS1 0.601 0.786 0.955 0.484 0.266
rs1903908 CG2039140 0.640 0.959 0.714 0.273 0.504
rs6265 BDNF 0.196 0.375 0.462 0.903 0.913
rs1385600 GAB2 0.760 0.319 0.865 0.624 0.968
rs2373115 GAB2 0.957 0.359 0.949 0.702 0.939
rs2070045 SORL1 0.443 0.952 0.746 0.170 0.357
rs3824968 SORL1 0.716 0.849 0.898 0.344 0.510
rs11610206 FAM113B 0.268 0.574 0.572 0.572 0.692
rs11159647 14q31.2 0.275 0.883 0.749 0.277 0.989
rs1554948 TNK1 0.494 0.469 0.459 0.278 0.162
rs2471738 MAPT 0.509 0.401 0.165 0.033 0.202
rs1800764 ACE 0.475 0.152 0.736 0.153 0.849
rs3746319 ZNF224 0.003 0.031 0.022 0.089 0.007
rs3826656 CD33 0.534 0.310 0.928 0.408 0.767
rs3745833 GALP 0.212 0.433 0.245 0.956 0.637
rs1799990 PRNP 0.652 0.952 0.877 0.982 0.650
rs8192708 PCK1 3.69610
24 0.0010 0.051 0.012 0.073
rs5984894 PCDH11X 0.769 0.799 0.460 0.722 0.877
e4 APOE 2.36610
212 1.22610
27 5.60610
26 1.22610
24 5.46610
24
e2 APOE 0.130 0.943 0.555 0.126 0.665
doi:10.1371/journal.pone.0011244.t005
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neuropathologic subtypes, we found that the association of
ZNF224 on AD pathology appeared to be due to a predominant
effect on neurofibrillary tangles. Indeed, when we substituted a
term for neurofibrillary tangles instead of the global pathology
variable in our regression model, the effect of the ZNF224 variant
on global cognition was reduced by 64%, and was no longer
significant (Beta=20.14, p=0.21), whereas tangles showed a
robust association with cognitive impairment (p,2610
216). These
results are consistent with a sequence of events whereby an effect
on the formation of neurofibrillary tangles accounts for the
association of the ZNF224 allele with cognitive function.
In contrast to ZNF224, the PCK1 locus showed a relatively
selective association with global cognition, but not with global
pathology. For this locus, an additive model of inheritance was a
best fit for our data, and PCK1 explained 3.4% (Beta=0.49,
p=1.02610
24) of the variance in global cognition proximate to
death. We next used multiple linear regression to test whether the
association of this SNP on cognitive impairment is predominantly
independent of AD pathology. Indeed, after inclusion of a model
term for global AD pathology, the PCK1 SNP (rs8192708)
remained associated with global cognition (Beta=0.37,
p=0.002), despite the strong, independent association between
pathology and cognition (Beta=21.22, p,2610
216; Table 7).
Given our finding of an association with neuritic plaques, we
substituted a model term for neuritic pathology instead of the
global pathology variable; however, despite a modest reduction in
the effect size, the relation between PCK1 and cognitive
impairment remained significant (Beta=0.31, p=0.005; Table 7).
Besides AD-related pathology, Lewy bodies and infarcts are the
two additional brain pathologies most commonly seen in
association with age-related cognitive decline [39]. We therefore
investigated whether the association of PCK1 on global cognition
might be mediated by either Lewy bodies or infarcts, by including
relevant terms into our regression model (Table 8). Again, the
association between PCK1 and global cognition remained
Table 6. Detailed genotype-phenotype data and statistical modeling.
Minor Allele Homozygotes Heterozygotes Major Allele Homozygotes
Variant
No.
Subjects
(Frq.) Genotype
Mean
Score
(SD)
1
No.
Subjects
(Frq.) Genotype
Mean
Score
(SD)
1
No.
Subjects
(Frq.) Genotype
Mean
Score
(SD)
1
Beta
(SE) p (Model)
2
Variance
Explained
Global
Pathology
rs3746319
(ZNF224)
11 (0.03) AA 0.749
(0.486)
113 (0.28) AG 0.811
(0.427)
290 (0.70) GG 0.687
(0.398)
0.13
(0.04)
0.003 (D) 2
APOE e2 2 (0.005) - 0.388
(0.010)
62 (0.15) - 0.576
(0.409)
340 (0.84) - 0.754
(0.409)
20.20
(0.05)
2.11610
24 (A) 3.1
APOE e4 9 (0.02) - 0.906
(0.437)
110 (0.27) - 1.011
(0.357)
285 (0.71) - 0.609
(0.376)
0.35
(0.04)
,2.0610
216 (A) 18.9
Global
Cognition
rs3746319
(ZNF224)
11 (0.03) AA 20.759
(1.15)
113 (0.27) AG 21.19
(1.27)
289 (0.70) GG 20.79
(1.15)
20.39
(0.12)
0.002 (D) 2.1
rs8192708
(PCK1)
8 (0.02) GG 20.413
(0.670)
81 (0.20) GA 20.550
(0.947)
324 (0.78) AA 21.00
(1.24)
0.49
(0.13)
1.02610
24 (A) 3.4
APOE e2 2 (0.01) - 20.235
(1.11)
62 (0.15) - 20.788
(1.21)
339 (0.84) - 20.916
(1.19)
0.23
(0.15)
0.12 (A) 0.36
APOE e4 9 (0.02) - 21.27
(1.50)
109 (0.27) - 21.41
(1.28)
285 (0.71) - 20.684
(1.09)
20.69
(0.11)
4.37610
210 (A) 9
1 Mean quantitative trait outcome measure is reported, square root transformed for global pathology.
2 Associations were tested with additive (A), dominant (D), or recessive models to identify the best fit.
doi:10.1371/journal.pone.0011244.t006
Table 7. Distinct pathways of ZNF224 and PCK1 association with cognition.
Model 1
1 Model 2
2 Model 3
3
Beta (SE) p Beta (SE) p Beta (SE) p
rs3746319 (ZNF224) 20.39 (0.12) 0.002 20.22 (0.11) 0.05 20.14 (0.11) 0.213
Pathology Measure - - Global Pathology 21.27 (0.13) ,2610
216 Neurofibrillary Tangles 21.40 (0.12) ,2610
216
rs8192708 (PCK1) 0.50 (0.120) 1.02610
24 0.37 (0.12) 0.002 0.31 (0.11) 0.005
Pathology Measure - - Global Pathology 21.22 (0.13) ,2610
216 Neuritic Plaques 20.96 (0.10) ,2610
216
1 Core regression model includes terms for age at death, gender, and years of education.
2 Model additionally includes a term for the global AD pathology measure.
3 Model additionally includes a term for either neurofibrillary tangles or neuritic plaques.
doi:10.1371/journal.pone.0011244.t007
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24), and PCK1 continued to
explain 3% of the residual variance in global cognition in our
cohort after adjusting for the three most common brain
pathologies associated with dementia. Common variation at the
PCK1 locus has also been associated with type 2 diabetes in a
number of independent studies [40–42]. Since diabetes has also
been implicated as a risk factor for age-related cognitive decline
[31], we examined whether diabetes mediates the association of
PCK1 with cognitive impairment. However, adjusting for diabetes
diagnosis in our linear regression model did not significantly
attenuate the association of PCK1 with global cognition (Be-
ta=0.370, p=0.001).
Discussion
In this study, by genotyping a panel of loci within two cohorts of
subjects with detailed cognitive and neuropathological character-
ization, we evaluate intermediate phenotypes as a tool for the
functional dissection of candidate AD susceptibility loci. Using the
extensively validated APOE locus, we previously demonstrated that
intermediate traits enhance statistical power to detect associations,
even in studies of modest sample size. Here, using the same
strategy, we present evidence supporting the possible role of two
additional loci in influencing age-related cognitive decline and AD
neuropathology. Specifically, the ZNF224 locus is associated with a
quantitative measure of global AD pathology, and both ZNF224
and PCK1 are associated with a summary measure of global
cognition proximate to death. Using separate quantitative traits for
each of the predominant AD pathological features, we document
associations between GALP and PCK1 and diffuse and neuritic
plaque pathology, respectively, whereas ZNF224 showed a
relatively selective association with neurofibrillary tangle pathol-
ogy. Finally, in a series of statistical mediation analyses, we tested
hypotheses about the causal chain of events linking genetic
variation in the ZNF224 and PCK1 loci with cognitive decline, with
strikingly different outcomes. In the case of ZNF224, we find that
AD pathology, and more specifically, neurofibrillary tangles
mediate an association with cognitive impairment. In contrast,
we find that the association between PCK1 and cognition is largely
independent of not only AD pathology, but also Lewy bodies, and
infarcts, which together comprise the three most common known
brain pathologies associated with dementia [39,43].
Both ZNF224 and PCK1 were initially implicated by AD GWA
studies; however, neither locus has yet been consistently replicated
in subsequent genetic studies, and little is known about their
potential mechanism of action in disease pathogenesis. The
ZNF224 locus encodes a Kruppel-associated box-containing
zinc-finger protein that is widely expressed, including in the adult
brain, and likely functions as a transcriptional repressor [44,45].
The SNP evaluated in this study, rs3746319, encodes a missense
mutation causing a Lys to Glu change at position 640, which falls
near the C-terminus within one of 19 zinc-finger repeat motifs.
However, we do not yet know enough about ZNF224 protein
structure and function to speculate further on how this variant
might promote neurofibrillary tangle formation and subsequent
cognitive impairment, and further investigation will be required to
determine if rs3746319 is the causal variant and whether ZNF224
is indeed the causal gene. The PCK1 gene encodes phosphoenol-
pyruvate carboxykinase 1, which catalyzes the rate-limiting step of
gluconeogenesis [46]. The SNP genotyped in our study,
rs8192708, is also a missense mutation, causing an Ile to Val
change at position 267; however, the functional consequences of
this change, if any, are not known. PCK1 variants have also been
suggested to be associated with diabetes [40–42], and indepen-
dently, diabetes has been identified as a risk factor for the
development of dementia [31]. In our mediation analysis,
adjusting for the effect of diabetes diagnosis did not account for
the association of PCK1 and cognitive impairment; however, it is
possible that an appropriate intermediate phenotype, such as
direct measurements of blood glucose or hemoglobin A1c, might
allow detection of mediation. In another study performed in the
same cohort, a relation was found between diabetes and infarcts
[47]; however, we were also unable to mediate the PCK1
association by including a model term for cerebral infarctions.
Our finding that the PCK1 association with cognitive decline is not
explained by AD pathology, Lewy bodies, or infarcts suggests that
this locus might influence additional, unmeasured pathologies. For
example, whereas our analyses adjusted for macroscopic infarcts,
PCK1 may instead primarily influence microscopic forms of
cerebrovascular injury. Further, while our intermediate pathologic
phenotype accounts for amyloid plaques and neurofibrillary
tangles, it does not capture levels of soluble, but potentially still
neurotoxic, forms of amyloid or tau pathology [48,49]. Alterna-
tively, variation at PCK1 might influence one or multiple steps in
the cascade of events predicted to occur downstream of amyloid,
tangles and other pathologies, such as synapse loss, inflammation,
and/or cell death pathways.
Unexpectedly, the variants in ZNF224 and PCK1 show opposite
directions of allelic effects for association with AD intermediate
phenotypes in our cohort compared to their association with AD
diagnosis in the initial GWA studies. In other words, the alleles
associated with increased AD risk in the initial reports (rs3746319
G
and rs8192708
G) are actually protective against cognitive decline in
our cohort. Importantly, this discrepancy is not accounted for by
our use of intermediate phenotypes, as the ZNF224 and PCK1
SNPs show consistent direction of affect on AD diagnosis in our
study population (Table 3). Such ‘‘flip-flop’’ associations have been
reported with increasing frequency as GWA scans are completed
for many common diseases, and replication efforts are subse-
quently undertaken [50]. Indeed, in the case of PCK1, two prior
replication studies found evidence that the major allele,
rs8192708
A, may increase risk for dementia, consistent with our
results suggesting an association between this allele and both
cognitive decline and AD [4,38].
The interpretation of reversals in the direction of variant
associations between different study cohorts remains controversial
[50]. The most common explanation for such observations are
that they are in fact spurious and representative of chance
fluctuations around the null hypothesis. However, in our study, the
strongly suggestive statistical evidence for the associations between
ZNF224 and PCK1 with AD intermediate phenotypes makes their
arising by chance less likely; and additionally, the reversals of
allelic effect are seen with both loci in our analysis. Instead, we
Table 8. PCK1 association with cognition is largely
independent of AD pathology, infarcts, and Lewy bodies.
Model 4
1
Beta (SE) p
rs8192708 (PCK1) 0.39 (0.11) 2.04610
24
AD Pathology 21.24 (0.12) ,2610
216
Infarcts 20.39 (0.10) 1.75610
24
Lewy bodies 20.52 (0.11) 3.84610
25
1 Model also includes terms for age, gender, and education.
doi:10.1371/journal.pone.0011244.t008
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are more likely to be responsible for our observations. The
Religious Orders Study (ROS) and Rush Memory and Aging
Project (MAP), from which our study cohort is based, are
prospective, longitudinal studies in which subjects from the
community are recruited non-demented at baseline (mean
age =75 and 79, for ROS and MAP respectively). All cases of
clinical AD are therefore incident within our cohort. In contrast,
similar to nearly all AD GWA studies performed to date, the initial
reports of association with the PCK1 and ZNF224 loci come from
AD cases recruited from a neurology clinic population with
prevalent dementia. In addition, whereas subjects in our study
were recruited at approximately similar ages to the GWA cohorts,
they were significantly older at the time of last clinical evaluation
and autopsy (mean age of death =87). Studies with different
designs (cross-sectional vs. prospective) and varying methods of
subject ascertainment can generate contradictory epidemiological
findings, for example due to survival bias. If an AD risk allele is
associated with earlier age of dementia onset; it might be under-
represented in the prospective cohort, which requires subjects to
be non-demented at enrollment; and therefore, might subsequent-
ly appear to be a protective allele. ‘‘Flip-flop’’ associations might
additionally arise from variation in linkage disequilibrium
structure in the genomic region of interest between the cohorts
in different studies. In fact, both the ZNF224 and PCK1 SNPs fall
under modest recombination peaks, based on HapMap data [51].
Although both our study and the GWA analyses were conducted
in subjects of European ancestry, it remains possible that sampling
variation between two populations of similar ethnicity might lead
to the association reversal that we have observed, as recombina-
tion could distribute our tag SNP onto haplotypes that are
different from that harboring the causal variant [50]. Ultimately,
further analysis of both SNPs and fine mapping of each locus in
larger study samples will be required to validate both PCK1and
ZNF224 as AD susceptibility loci, and resolve which allele may
increase risk for disease.
Of the thirty-four SNPs evaluated in our study, both of the loci
that we found to be associated with AD intermediate phenotypes
were initially identified by GWA studies, suggesting the power of
this unbiased approach to identify genes that might be overlooked
by prevailing hypotheses of disease biology. Our study was
initiated prior to the recent report of two large AD case/control
GWA studies which independently identified three new suscepti-
bility genes, CLU, CR1, and PICALM [15,16]. In a parallel effort,
we recently found that CR1 is associated with age-related cognitive
decline in our study cohorts; and further, that this association was
mediated by an effect on amyloid pathology (Chibnik et al.,
submitted). The power of a GWA study design and the types of
genes one expects to discover are tightly linked to the selected
phenotypic outcome. To the extent possible, the chosen outcome
measure should be closely matched to the underlying biology
responsible for the heritable trait variation of interest. In autopsy
cohort studies of aged individuals in the community setting, most
subjects with probable AD demonstrate multiple brain pathologies
[52]. Based on our results, we believe that intermediate
pathological and cognitive traits have great promise to enhance
gene discovery and for functional characterization of loci that
emerge from current AD GWA studies.
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